References
- Shetab Boushehri MA, Dietrich D, Lamprecht A. Nanotechnology as a platform for the development of injectable parenteral formulations: a comprehensive review of the Know-Hows and state of the art. Pharm. 2020;12(6):510. doi: 10.3390/pharmaceutics12060510
- Rahnfeld L, Luciani P. Injectable lipid-based depot formulations: where do we stand? Pharmaceutics. 2020;12(6):1–28. doi: 10.3390/pharmaceutics12060567
- Wong J, Brugger A, Khare A, et al. Suspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspects. Adv Drug Delivery Rev. 2008;60(8):939–954. doi: 10.1016/j.addr.2007.11.008
- Sosnik A, Cohn D. Ethoxysilane-capped PEO – PPO – PEO triblocks: a new family of reverse thermo-responsive polymers. Biomaterials. 2004;25(14):2851–2858. doi: 10.1016/j.biomaterials.2003.09.057
- Sodyum D, Polimerik Y. In situ hydrogel formulation for intra-articular application of diclofenac sodium-loaded polymeric nanoparticles. 2017;14:56–64. doi: 10.4274/tjps.84803
- Bajwa K, Qorri B, Decarlo A, et al. Recent advances in “smart” delivery systems for extended drug release in cancer therapy. 2018:4727–4745. doi: 10.2147/IJN.S168053
- Park K, Otte A, Sharifi F, et al. Formulation composition, manufacturing process, and characterization of poly(lactide-co-glycolide) microparticles. J Control Release. 2021;329:1150–1161. doi: 10.1016/j.jconrel.2020.10.044
- Zhong H, Chan G, Hu Y, et al. A comprehensive map of FDA-Approved pharmaceutical products. Pharmaceutics. 2018;10(4):1–19. doi: 10.3390/pharmaceutics10040263
- Larsen SW, Thing MA, Larsen C. Oily (Lipophilic) Solutions and Suspensions. In: Wright J, Burgess D, editors. Long Acting Injections and Implants. Springer, Boston, MA: Advances in Delivery Science and Technology; 2012. doi: 10.1007/978-1-4614-0554-2_7
- Bauer W, Short CL, Bennett GA. The manner of removal of proteins from normal joints. J Exp Med. 1933;57(3):419. doi: 10.1084/jem.57.3.419
- Simkin BPA, Bassett JE, Koh E. Synovial perfusion in the human knee: a methodological analysis. Semin Arthritis Rheum. 1995;25(1):56–66. doi: 10.1016/S0049-0172(95)80018-2
- Chien YW. Long-acting parenteral drug formulations. PDA J Pharm Sci Technol. 1981;35:106–139.
- Zuidema J, Kadir F, Titulaer HAC, et al. Release and absorption rates of intramuscularly and subcutaneously injected pharmaceuticals (II). Int J Pharm. 1994;105(3):189–207. doi: 10.1016/0378-5173(94)90103-1
- Armstrong NA, James KC. Drug release from lipid-based dosage forms. II. Int J Pharm. 1980;6(3–4):195–204. doi: 10.1016/0378-5173(80)90104-0
- Luo JP, Hubbard JW, Midha KK. The roles of depot injection sites and proximal lymph nodes in the presystemic absorption of fluphenazine decanoate and fluphenazine: Ex Vivo experiments in rats. Pharm Res. 1998;15:1485–1489.
- Minto CF, Howe C, Wishart S, et al. Pharmacokinetics and pharmacodynamics of nandrolone esters in oil vehicle: effects of ester, injection site and injection volume. J Pharmacol Exp Ther. 1997;281(1):93–102.
- Weng Larsen S, Larsen C. Critical factors influencing the in vivo performance of long-acting Lipophilic Solutions—impact on in vitro release method design. Aaps J. 2009;11(4):762–770. doi: 10.1208/s12248-009-9153-9
- Rabe T, Grunwald K, Feldmann K, et al. Treatment of hyperandrogenism in women. Gynecol Endocrinol. 1996;10(sup3):1–44. doi: 10.3109/09513599609045658
- Fda. Delatestryl ® (testosterone enanthate injection, USP). [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/009165s034lbl.pdf
- Fda. Clopixol depot [Internet]. [cited 2022 Aug 3]. Available from: https://www.lundbeck.com/content/dam/lundbeck-com/americas/canada/products/files/clopixol_product_monograph_english.pdf
- Fda. Depo ®-Estradiol [Internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/085470s015lbl.pdf
- FDA label. Depo-Testosterone®. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/085635s040lbl.pdf
- Agent A. FLUANXOL ® flupentixol tablets (as flupentixol dihydrochloride) 0.5 mg, 3 mg, and 5 mg Pr FLUANXOL ® DEPOT flupentixol decanoate intramuscular injection 2% and 10% flupentixol decanoate. 2017.
- Androcur depot. ANDROCUR ® DEPOT cyproterone acetate injection 100 mg/mL [internet]. 2011 [cited 2022 Aug 3]. Available from: https://pdf.hres.ca/dpd_pm/00012618.PDF
- Fda. HALDOL ® decanoate 50 (haloperidol) HALDOL ® decanoate 100 (haloperidol) for IM injection only WARNING increased mortality in elderly patients with dementia-related psychosis. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/018701s073lbl.pdf
- Fda. Faslodex (fulvestrant) injection label [internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021344s015lbl.pdf
- Makena. Makena (hydroxyprogesterone caproate) injection label [internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021945s005lbl.pdf
- Naldebain for pain management of laparoscopic cholecystectomy - full text view - ClinicalTrials.Gov. [cited 2022 Aug 3]. Available from: https://clinicaltrials.gov/ct2/show/NCT04808544
- Lengyel M, Kállai-Szabó N, Antal V, et al. Microparticles, microspheres, and microcapsules for advanced drug delivery. Sci Pharm. 2019;87(3):20. doi: 10.3390/scipharm87030020
- Erbetta CDC, Alves RJ, Resende JM, et al. Synthesis and characterization of Poly(D,hypenCapswithspaceRetainColl1actide-co-Glycolide) copolymer. J Biomater Nanobiotechnol. 2012;3(2):208–225. doi: 10.4236/jbnb.2012.32027
- Hadar J, Skidmore S, Garner J, et al. Characterization of branched poly(lactide-co-glycolide) polymers used in injectable, long-acting formulations. J Control Release. 2019;304:75–89. doi: 10.1016/j.jconrel.2019.04.039
- O’donnell PB, Mcginity JW. Preparation of microspheres by the solvent evaporation technique. Adv Drug Deliv Rev. 1997;28(1):25–42. doi: 10.1016/S0169-409X(97)00049-5
- Thomasin C, Nam-Trân H, Merkle HP, et al. Drug microencapsulation by PLA/PLGA coacervation in the light of thermodynamics. 1. Overview and theoretical considerations. J Pharm Sci. 1998;87(3):259–268. doi: 10.1021/js970047r
- Doty AC, Weinstein DG, Hirota K, et al. Mechanisms of in vivo release of triamcinolone acetonide from PLGA microspheres. J Control Release. 2017;256:19–25. doi: 10.1016/j.jconrel.2017.03.031
- Sophocleous AM, Desai KGH, Mazzara JM, et al. The nature of peptide interactions with acid end-group PLGAs and facile aqueous-based microencapsulation of therapeutic peptides. J Control Release. 2013;172(3):662–670. doi: 10.1016/j.jconrel.2013.08.295
- trelstar. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-288_Trelstar_medr_P1.pdf
- Fda. LUPRON DEPOT (leuprolide acetate for depot suspension). [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020517s036_019732s041lbl.pdf
- Fda. Sandostatin LAR depot. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021008s043lbl.pdf
- Triptodur. [Internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208956Orig1s000Lbl.pdf
- Fda. risperdal consta. [Internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021346_s31_s35_s38_s39lbl.pdf
- Fda. VIVITROL (naltrexone for extended-release injectable suspension) label. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021897s015lbl.pdf
- Fda. Bydureon. [Internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022200s026lbl.pdf
- Signifor LAR. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/203255s004lbl.pdf
- Fda. Zilretta [Internet]. 2017 [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208845s000lbl.pdf
- Vintiloiu A, Leroux JC. Organogels and their use in drug delivery — a review. J Control Release. 2008;125(3):179–192. doi: 10.1016/j.jconrel.2007.09.014
- Hatefi A, Amsden B. Biodegradable injectable in situ forming drug delivery systems. J Control Release. 2002;80(1–3):9–28. doi: 10.1016/S0168-3659(02)00008-1
- ELIGARD. Eligard [Internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021731s005,021488s010,021379s010,021343s015lbl.pdf
- fda. PERSERIS [Internet]. [cited 2022 Aug 3]. Available from: https://www.acccessdata.fda.gov/drugsatfda_docs/label/2018/210655s000lbl.pdf
- Fda. SUBLOCADE [Internet]. [cited 2022 Aug 3]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2018/2110655s000lbl.pdf
- Fda. ATRIDOX. [Internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/050751s015lbl.pdf
- Fda. SUSTOL [Internet]. [cited 2022 Aug 3]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/050751s015lbl.pdf
- Zynrelef. Zynrelef [Internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211988s000lbl.pdf
- Drugs@FDA: FDA-Approved Drugs. Bridal [Internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210136
- Fda. Posimir [Internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/204803s000lbl.pdf
- Ravivarapu HB, Moyer KL, Dunn RL. Parameters affecting the efficacy of a sustained release polymeric implant of leuprolide. Int J Pharm. 2000;194(2):181–191. doi: 10.1016/S0378-5173(99)00371-3
- Shah JC, Sadhale Y, Chilukuri DM. Cubic phase gels as drug delivery systems. Adv Drug Deliv Rev. 2001;47(2–3):229–250. doi: 10.1016/S0169-409X(01)00108-9
- Spicer PT, Hayden KL, Lynch ML, et al. Novel process for producing cubic liquid crystalline nanoparticles (cubosomes). Langmuir. 2001;17(19):5748–5756. doi: 10.1021/la010161w
- Wörle G, Drechsler M, Koch MHJ, et al. Influence of composition and preparation parameters on the properties of aqueous monoolein dispersions. Int J Pharm. 2007;329(1–2):150–157. doi: 10.1016/j.ijpharm.2006.08.023
- Barauskas J, Johnsson M, Joabsson F, et al. Cubic phase nanoparticles (cubosome): principles for controlling size, structure, and stability. Langmuir. 2005;21(6):2569–2577. doi: 10.1021/la047590p
- Wörle G, Siekmann B, Bunjes H. Effect of drug loading on the transformation of vesicular into cubic nanoparticles during heat treatment of aqueous monoolein/poloxamer dispersions. Eur J Pharm Biopharm. 2006;63(2):128–133. doi: 10.1016/j.ejpb.2005.11.004
- Wadsäter M, Barauskas J, Nylander T, et al. Formation of highly structured cubic micellar lipid nanoparticles of soy phosphatidylcholine and glycerol dioleate and their degradation by triacylglycerol lipase. ACS Appl Mater Interfaces. 2014;6(10):7063–7069. doi: 10.1021/am501489e
- Parent M, Nouvel C, Koerber M, et al. PLGA in situ implants formed by phase inversion: critical physicochemical parameters to modulate drug release. J Control Release. 2013;172(1):292–304. doi: 10.1016/j.jconrel.2013.08.024
- Stewart SA, Domínguez-Robles J, Donnelly RF, et al. Implantable polymeric drug delivery devices: classification, manufacture, materials, and clinical applications. Polym. 2018;10(12):1379. doi: 10.3390/polym10121379
- O’Brien MN, Jiang W, Wang Y, et al. Challenges and opportunities in the development of complex generic long-acting injectable drug products. J Control Release. 2021;336:144–158. doi: 10.1016/j.jconrel.2021.06.017
- Vippagunta SR, Brittain HG, Grant DJW. Crystalline solids. Adv Drug Deliv Rev. 2001;48(1):3–26. doi: 10.1016/S0169-409X(01)00097-7
- Healy AM, Worku ZA, Kumar D, et al. Pharmaceutical solvates, hydrates and amorphous forms: a special emphasis on cocrystals. Adv Drug Deliv Rev. 2017;117:25–46. doi: 10.1016/j.addr.2017.03.002
- Zhang GGZ, Law D, Schmitt EA, et al. Phase transformation considerations during process development and manufacture of solid oral dosage forms. Adv Drug Deliv Rev. 2004;56(3):371–390. doi: 10.1016/j.addr.2003.10.009
- Bharate SS. Recent developments in pharmaceutical salts: FDA approvals from 2015 to 2019. Drug Discov Today. 2021;26(2):384–398. doi: 10.1016/j.drudis.2020.11.016
- Mishra B, Singh J. Novel drug delivery systems and significance in respiratory diseases. Targeting Chronic Inflammatory Lung Diseases Using Advanced Drug Delivery Systems. 2020. p. 57. doi: 10.1016/B978-0-12-820658-4.00004-2. Epub 2020 Sep 18. PMCID: PMC7499344.
- Triesence. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022223,022048lbl.pdf
- Ryanodex [Internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205579s000lbl.pdf
- Fda. zyprexa relprevv [Internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022173lbl.pdf
- Fda. trelstar [Internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020715s040,021288s035,022427s015lbl.pdf
- Abilify maintena. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202971s008lbl.pdf
- Fda. invega sustena [Internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022264s023lbl.pdf
- Fda. invega triniza [Internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207946s003lbl.pdf
- Fda. aristada [Internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207533s000lbl.pdf
- Fda. REZZAYO [Internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217417s000lbl.pdf
- Pattni BS, Chupin VV, Torchilin VP. New developments in liposomal drug delivery. Chem Rev. 2015;115(19):10938–10966. doi: 10.1021/acs.chemrev.5b00046
- Woodle MC, Lasic DD. Sterically stabilized liposomes. Biochim Biophys Acta. 1992;1113(2):171–199. doi: 10.1016/0304-4157(92)90038-C
- Torchilin VP. Polymer-coated long-circulating microparticulate pharmaceuticals. J Microencapsul. 1998;15(1):1–19. doi: 10.3109/02652049809006831
- Lasic DD, Martin FJ, Gabizon A, et al. Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochim Biophys Acta. 1991;1070(1):187–192. doi: 10.1016/0005-2736(91)90162-2
- Ishida T, Maeda R, Ichihara M, et al. Accelerated clearance of PEGylated liposomes in rats after repeated injections. J Control Release. 2003;88(1):35–42. doi: 10.1016/S0168-3659(02)00462-5
- Ishihara T, Maeda T, Sakamoto H, et al. Evasion of the accelerated blood clearance phenomenon by coating of nanoparticles with various hydrophilic polymers. Biomacromolecules. 2010;11(10):2700–2706. doi: 10.1021/bm100754e
- Alphandéry E, Grand-Dewyse P, Lefèvre R, et al. Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects. Expert Rev Anticancer Ther. 2015;15(10):1233–1255. doi: 10.1586/14737140.2015.1086647
- Murry DJ, Blaney SM. Clinical pharmacology of encapsulated sustained-release cytarabine. Ann Pharmacother. 2000;34(10):1173–1178. doi: 10.1345/aph.19347
- Landon CD, Park JY, Needham D, et al. Nanoscale drug delivery and hyperthermia: the materials design and preclinical and clinical testing of low temperature-sensitive liposomes used in combination with mild hyperthermia in the treatment of local cancer. Open Nanomed J. 2011;3(1):24–37. doi: 10.2174/1875933501103010038
- Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug Release1 | cancer research | American association for cancer research [Internet]. [cited 2024 Apr 20]. Available from: https://aacrjournals.org/cancerres/article/60/24/6950/506979/Efficacy-of-Liposomes-and-Hyperthermia-in-a-Human
- Fda. EXPAREL (bupivacaine liposome injectable suspension) [Internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022496s9lbl.pdf
- Fda. Doxil [Internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050718s029lbl.pdf
- Fda. Onivyde [Internet]. 2015 [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207793lbl.pdf
- AmBisome® (amphotericin B) liposome for injection. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050740s016lbl.pdf
- Drugs@FDA: FDA-Approved Drugs [Internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050724
- Fda. DEPOCYT (cytarabine liposome injection) label [internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021041s031lbl.pdf
- Marqibo [Internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202497s011lbl.pdf
- Fda. Vyxeos [Internet]. 2017 [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s000lbl.pdf
- Fda. Arikayce [Internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207356s000lbl.pdf
- Fda. onpattro [Internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210922s000lbl.pdf
- Fda. visudyne [Internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021119s027lbl.pdf
- Liu JKH. The history of monoclonal antibody development – progress, remaining challenges and future innovations. Ann Med Surg. 2014;3(4):113. doi: 10.1016/j.amsu.2014.09.001
- Yao H, Jiang F, Lu A, et al. Methods to design and synthesize antibody-drug conjugates (ADCs). Int J Mol Sci. 2016;17(2):194. doi: 10.3390/ijms17020194
- Walsh SJ, Bargh JD, Dannheim FM, et al. Site-selective modification strategies in antibody–drug conjugates. Chem Soc Rev. 2021;50(2):1305–1353. doi: 10.1039/D0CS00310G
- Zhao P, Zhang Y, Li W, et al. Recent advances of antibody drug conjugates for clinical applications. Acta Pharm Sin B. 2020;10(9):1589–1600. doi: 10.1016/j.apsb.2020.04.012
- Bargh JD, Isidro-Llobet A, Parker JS, et al. Cleavable linkers in antibody–drug conjugates. Chem Soc Rev. 2019;48(16):4361–4374. doi: 10.1039/C8CS00676H
- Fda. mylotarg [Internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761060lbl.pdf
- Fda. adcetris [Internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125388_s056s078lbl.pdf
- Kadcyla [Internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125427lbl.pdf
- Fda. besponsa [Internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761040s000lbl.pdf
- Polivy. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761121s000lbl.pdf
- Padcev. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf
- Enhertu. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761139s011lbl.pdf
- Trodelvy. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761115s009lbl.pdf
- Fda. Blenrep [Internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761158s000lbl.pdf
- Fda. Zynlonta [Internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761196s000lbl.pdf
- Fda. Tivdak (tisotumab vedotin-tftv) for injection. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761208s005lbl.pdf
- Fda, cder. LUNSUMIOTM. [Internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/761263Orig1s000ltr.pdf
- Fda, cder. TZIELDTM. [Internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/761183Orig1s000ltr.pdf
- Fda, Cder. ELAHERE. [Internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761310Orig1s000MultidisciplineR.pdf
- Fda, cder. TECVAYLITM. [Internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761291s000lbl.pdf
- Fda. IMJUDO®.[Internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761289lbl.pdf
- Fda, cder. SPEVIGO®.[Internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761244s000lbl.pdf
- Fda, cder. Opdualag®.[Internet].[ cited 2022 Aug 03]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/761234Orig1s000ltr.pdf
- Fda, cder. Enjaymo®.[Internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761164Orig1s000OtherR.pdf
- Fda, cder. Vabysmo®.[Internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/761235Orig1s000ltr.pdf
- Fda, cder. KIMMTRAK®.[Internet]. [cited 2022 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761228Orig1s000OtherR.pdf
- Fda. LEQEMBI [Internet]. [cited 2023 Aug 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761269s001lbl.pdf
- Fda. Zynyz [Internet]. [cited 2023 Aug 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761334s000lbl.pdf
- Fda. ELFABRIO® [Internet]. [cited 2023 Aug 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761161s000lbl.pdf
- Fda. EPKINLYTM [internet]. [cited 2023 Aug 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761324s000lbl.pdf
- Fda. Columvi. [cited 2023 Aug 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761309s000lbl.pdf
- Fda. RYSTIGGO® [Internet]. [cited 2023 Aug 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761286s000lbl.pdf
- Fda. NGENLA [Internet]. [cited 2023 Aug 09]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761184Orig1s000Corrected_lbl.pdf
- Fda. BEYFORTUS [Internet]. [cited 2023 Aug 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761328s000lbl.pdf
- Fda. LAMZEDE [Internet]. [cited 2023 Aug 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761278s000lbl.pdf
- Perez HL, Cardarelli PM, Deshpande S, et al. Antibody–drug conjugates: current status and future directions. Drug Discov Today. 2014;19(7):869–881. doi: 10.1016/j.drudis.2013.11.004
- Tolcher AW, Sugarman S, Gelmon KA, et al. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol. 1999;17(2):478–478. doi: 10.1200/JCO.1999.17.2.478
- Okamoto H, Oitate M, Hagihara K, et al. Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice. Xenobiotica. 2020;50(10):1242–1250. doi: 10.1080/00498254.2020.1755909
- Seligson JM, Patron AM, Berger MJ, et al. Sacituzumab Govitecan-hziy: an antibody-drug conjugate for the treatment of refractory, metastatic, triple-negative breast cancer. Ann Pharmacother. 2021;55(7):921–931. doi: 10.1177/1060028020966548
- Li WI, Anderson KW, Deluca PP. Kinetic and thermodynamic modeling of the formation of polymeric microspheres using solvent extraction/evaporation method. J Control Release. 1995;37(3):187–198. doi: 10.1016/0168-3659(95)00077-1
- Henriques J, Cardoso C, Vitorino C. On demand for new process analytical technologies applied to injectable drug products. Eur J Pharm Sci. 2019;137:104975. doi: 10.1016/j.ejps.2019.104975
- Kapoor DN, Katare OP, Kaurav H, et al. Development and optimization of in-situ forming microparticles for long term controlled delivery of deslorelin acetate. J Appl Pharm Sci. 2018;8:059–072.
- Kolluru LP, Atre P, Rizvi SAA. Characterization and applications of Colloidal Systems as versatile drug delivery carriers for parenteral formulations. Pharmaceuticals (Basel). 2021;14(2):108–112. doi: 10.3390/ph14020108
- Zagalo DM, Sousa J, Simões S. Quality by design (QbD) approach in marketing authorization procedures of non-biological complex drugs: a critical evaluation. Eur J Pharm Biopharm. 2022;178:1–24. doi: 10.1016/j.ejpb.2022.07.014
- Deng Y, Zhong G, Wang Y, et al. Quality by design approach for the preparation of fat-soluble vitamins lipid injectable emulsion. Int J Pharm. 2019;571:118717. doi: 10.1016/j.ijpharm.2019.118717
- Lagare RB, Huang YS, Bush COJ, et al. Developing a virtual flowability sensor for monitoring a pharmaceutical dry granulation line. J Pharm Sci. 2023;112(5):1427–1439. doi: 10.1016/j.xphs.2023.01.009
- Solomon D, Gupta N, Mulla NS, et al. Role of in vitro release methods in liposomal formulation development: challenges and regulatory perspective. Aaps J. 2017;19(6):1669–1681. doi: 10.1208/s12248-017-0142-0
- Grumbach C, Czermak P. Process analytical technology for the production of parenteral lipid emulsions according to good manufacturing practices. Process. 2022;10(6):1174. doi: 10.3390/pr10061174
- Cook J, Addicks W, Wu YH. Application of the biopharmaceutical classification system in clinical drug development—an industrial view. Aaps J. 2008;10(2):306. doi: 10.1208/s12248-008-9036-5
- Shen J, Burgess DJ. Accelerated in-vitro release testing methods for extended-release parenteral dosage forms. J Pharm Pharmacol. 2012;64(7):986–996. doi: 10.1111/j.2042-7158.2012.01482.x
- Shah KB, Patel PG, Khairuzzaman A, et al. An improved method for the characterization of supersaturation and precipitation of poorly soluble drugs using pulsatile microdialysis (PMD). Int J Pharm. 2014;468(1–2):64–74. doi: 10.1016/j.ijpharm.2014.04.012
- Greenwood R, Kendall K. Selection of suitable dispersants for aqueous suspensions of zirconia and titania powders using acoustophoresis. J Eur Ceram Soc. 1999;19(4):479–488. doi: 10.1016/S0955-2219(98)00208-8
- Wuchner K, Brown HC, Canal F, et al. Industry perspective on a holistic container closure integrity approach to parenteral combination products. Eur J Pharm Biopharm. 2024;194:20–35. doi: 10.1016/j.ejpb.2023.11.010
- Rini CJ, Roberts BC, Vaidyanathan A, et al. Enabling faster subcutaneous delivery of larger volume, high viscosity fluids. Expert Opin Drug Deliv. 2022;19(9):1165–1176. doi: 10.1080/17425247.2022.2116425
- Usach I, Martinez R, Festini T, et al. Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site. Adv Ther. 2019;36(11):2986–2996. doi: 10.1007/s12325-019-01101-6
- Farooque F, Wasi M, Mughees MM. Liposomes as drug delivery system: an updated review. J Drug Deliv Ther. 2021;11(5–S):149–158. doi: 10.22270/jddt.v11i5-S.5063
- Shabbits JA, Chiu GNC, Mayer LD. Development of an in vitro drug release assay that accurately predicts in vivo drug retention for liposome-based delivery systems. J Control Release. 2002;84(3):161–170. doi: 10.1016/S0168-3659(02)00294-8
- Park K, Otte A, Sharifi F, et al. Potential roles of the Glass Transition Temperature of PLGA Microparticles in drug release kinetics. Mol Pharm. 2020;18(1):18–32. doi: 10.1021/acs.molpharmaceut.0c01089
- Wagh A, Song H, Zeng M, et al. Challenges and new frontiers in analytical characterization of antibody-drug conjugates. MAbs. 2018;10(2):222–243. doi: 10.1080/19420862.2017.1412025